NovoCure (NVCR) vs SpyGlass Pharma (SGP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NovoCure is the larger company by market cap ($1.25 billion vs $1.02 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCR | SGP |
|---|---|---|
| Share price | $10.71 | $30.43 |
| Market cap | $1.25B | $1.02B |
| 1-day change | +0.19% | -1.14% |
| YTD return | -17.17% | — |
| 1-year return | -10.38% | — |
| 5-year return | -88.96% | — |
| EPS (TTM) | $-1.06 | $-2.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $655.35M | — |
| Revenue growth (YoY) | +8.28% | — |
| Net income (latest FY) | $-136.23M | $-39.87M |
| Gross margin | 74.54% | — |
| Operating margin | -23.47% | — |
| Net margin | -20.79% | — |
| 52-week high | $21.45 | $39.92 |
| 52-week low | $9.82 | $17.06 |
| Distance from 52-week high | -50.07% | -23.77% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +144.07% | +53.37% |
| Average volume | 1.51M | 114.63K |
| Shares outstanding | 116.92M | 33.46M |
| Employees | 1,605 | 88 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
About SpyGlass Pharma
SGP stock →SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
Health Care · Medical/Dental Instruments · 88 employees
NVCR vs SGP FAQ
Which is bigger, NovoCure or SpyGlass Pharma?
NovoCure (NVCR) is larger, with a market capitalization of $1.25B compared with $1.02B for SpyGlass Pharma (SGP).
Are NovoCure and SpyGlass Pharma in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.